VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of VBIV stock opened at $0.02 on Friday. VBI Vaccines has a fifty-two week low of $0.06 and a fifty-two week high of $1.35. The company has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.52.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.